Core Viewpoint - The article highlights the upcoming listing of Jianfa Zhixin Medical Technology Group Co., Ltd. on the Shenzhen Stock Exchange, emphasizing its role as a state-owned enterprise and a national high-value medical device distributor, focusing on direct sales and distribution, as well as providing centralized operation services for medical consumables [1]. Industry Overview - The medical device market is experiencing continuous growth driven by factors such as an aging population, rising chronic disease rates, and improved health awareness among residents [2]. - Despite the promising outlook, the medical device distribution sector faces significant challenges, including a fragmented supply chain, low operational efficiency, and issues with product identification and data standardization [2][3]. Company Innovations - Jianfa Zhixin is innovating through a "national integrated medical device distribution hub" model, which aims to improve management costs and efficiency while addressing traceability issues in the distribution of medical consumables [4][5]. - The company has developed a centralized management system for medical consumables, enhancing operational efficiency and reducing human resource demands through automation and smart technology [5][7]. Market Position and Growth - Jianfa Zhixin has strategically positioned itself in the high-value medical consumables market, achieving significant growth with contracts signed for centralized operation services with 60 hospitals, managing over 10 billion yuan in medical consumables [9]. - The company has reported impressive revenue growth, with projected revenues of 118.82 billion yuan in 2022, 154.43 billion yuan in 2023, and 179.23 billion yuan in 2024, reflecting a compound annual growth rate of 22.81% from 2022 to 2024 [9][10]. Competitive Advantage - Jianfa Zhixin's innovative solutions and operational efficiency have positioned it as a leader in the medical device distribution industry, with the highest revenue growth rate among major competitors [10][11]. - The company's focus on addressing industry pain points through its integrated distribution model and advanced supply chain management systems has garnered market recognition and facilitated rapid project implementation [11].

根据招股书介绍，建发致新为全国性的高值医疗器械流通商，主要从事医疗器械直销及分销业务，并 为终端医院提供医用耗材集约化运营（SPD）等服务。 近日， 上海建发致新医疗科技集团股份有限公司 （简称"建发致新"）披露 首次公开发行股票并在 创业板上市招股意向书。 公司拟首次公开发行 6300 余 万股， 申购日期为 9 月 16 日。 将开启 网上、网下申购 ， 发行总量：6319.3277万股 ， 网上发行：1011.05万股 ， 网上申购上限： 10000股 ， 发行市盈率 为 13.29倍，低于行业市盈率的25.73倍 。 2022至2024年，公司营业收入分别为118.82亿元、154.43亿元和179.23亿元， 业绩增长 迅 猛，年复合增长率为22.81%；同期扣非归母净利润为1.69亿元、1.91亿元和2.24亿元，年复合增 长率为14.99%，盈利能力强健稳定。 近年来，国内医疗器械流通领域竞争激烈，行业加速洗牌，市场集中度不断提升。建发致新以 何构 筑核心竞争力 ， 实现穿越周期 律 的持续增长？ 公司通过自主研发的原码解析技术，融合医疗器械唯一标识（UDI）的应用，对医疗器械产品进行一 物一码 ...